Vhfimmunotherapy.org Website Review

the viral hemorrhagic fever immunothera*eutic consortium, or vic, was established in 2014 to develop life-saving antibody thera*eutics against some of the world’s deadliest viruses. the vic represents a field-wide collaboration in which leading laboratories around the world have united to understand what features lead to antibody-mediated protection against these viruses and how we can more rapidly discover ideal treatments. this collaborative effort allows each laboratory to contribute their strengths in an*lytical techniques towards the identification, characterization, and validation of antibodies against the filoviridae and arenaviridae families. from isolating novel antibodies and testing them in vivo, to the structural an*lysis of the molecular mechanisms of neutralization, vic scientists contribute unique insights towards the overall characterization of a broad pool of antibodies. the consortium is funded through a national institute of health national institute of allergy and infectious diseases centers for excellence in translational research program. what lies beneath: structural features that confer pan-ebolavirus activity. the continuum of antibody epitopes on the gp waist viewed from the top (left) and side (right).  site a includes the conserved hydrophobic pocket beneath the gp2 tail recognized by adi-15878. antibodies interacting with epitopes in sites a-c are more likely to cross-reactive.  only one naturally occurring human antibody, adi-15878, is currently known that can … continued. characteristics of ebolavirus glycoprotein internal fusion loop recognition determine broad cross-reactivity. single particle negative stain electron microscopy of 6d6 fab fragment bound to ebov gp (side view, left and top view, right). the gp and fab are shown in grey and blue, respectively with the crystal structures shown as ribbon diagrams for reference. the 2014-2016 ebola virus. another facet of antibody-mediated protection: fc-driven immune effector function of antibodies against ebola virus glycoprotein.